Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

C4.4a-targeted antibody-drug conjugate

DRUG CLASS:

C4.4a-targeted antibody-drug conjugate

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

LYPD3 expression	Bladder Cancer	LYPD3 expression	Bladder Cancer	BAY1129980 Sensitive: D – Preclinical BAY1129980 Sensitive : D	BAY1129980 Sensitive: D – Preclinical BAY1129980 Sensitive : D
LYPD3 expression	Squamous Cell Carcinoma of Head and Neck	LYPD3 expression	Squamous Cell Carcinoma of Head and Neck	BAY1129980 Sensitive: D – Preclinical BAY1129980 Sensitive : D	BAY1129980 Sensitive: D – Preclinical BAY1129980 Sensitive : D
LYPD3 expression	Esophageal Squamous Cell Carcinoma	LYPD3 expression	Esophageal Squamous Cell Carcinoma	BAY1129980 Sensitive: D – Preclinical BAY1129980 Sensitive : D	BAY1129980 Sensitive: D – Preclinical BAY1129980 Sensitive : D
LYPD3 expression	Non Small Cell Lung Cancer	LYPD3 expression	Non Small Cell Lung Cancer	BAY1129980 Sensitive: D – Preclinical BAY1129980 Sensitive : D	BAY1129980 Sensitive: D – Preclinical BAY1129980 Sensitive : D